28 completed, 10 unknown, 8 recruiting, 7 terminated. 27 Phase 2, 9 Phase 1, 9 Phase 3, 6 Not applicable, 2 Early Phase 1.
Follow Cytoreduction Surgical Procedures: new trials by email Literature Review of Cytoreduction Surgical Procedures trials Research Report on Cytoreduction Surgical Procedures
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer Mitomycin (MM), FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Cytoreductive surgery - Locally Advanced Colorectal Cancer | Phase 3 | Recruiting | Maimónides Biomedical Research Institute of Córdoba | 1083 | 2026-05-26 | 2026-06-08 |
| Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not Debulking surgery - Pancreatic Neuroendocrine Tumor | Not applicable | Recruiting | Uppsala University | 200 | 2026-01-09 | 2026-01-22 |
| Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC Cytoreductive surgery, Immunochemotherapy - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Jianxing He | 118 | 2025-09-10 | 2025-09-16 |
| Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer KELIM, Carboplatin plus Paclitaxel, Interval debulking surgery - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | The University of Hong Kong | 18 | 2024-05-28 | 2025-07-02 |
| Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin - Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe) | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2024-01-31 | 2024-02-02 | |
| SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery Cytoreductive surgery, Neoadjuvant chemotherapy, Adjuvant chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Neoplasms | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 5000 | 2024-01-01 | 2024-01-25 | |
| Intraperitoneal LSTA1 in CRS-HIPEC CRS-HIPEC + LSTA1, CRS-HIPEC alone - Colorectal Cancer, Ovarian Carcinoma | Phase 1 | Withdrawn | University of California, San Diego | 2023-11-30 | 2024-08-20 | |
| Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Carboplatin or cisplatin, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Bevacizumab or biosimilar - Recurrent Ovarian Carcinoma | Not applicable | Recruiting | The University of Hong Kong | 18 | 2023-11-01 | 2025-06-11 |
| Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery Preoperative Evaluations, Cytoreductive Surgery, Perioperative Management - D010051, Ovarian Cancer | Completed | European Society of Gynaecological Oncology | 11383 | 2023-04-26 | 2026-05-05 | |
| Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver cytoreductive surgery, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT), Peptide receptor radionuclide therapy (PRRT) - Pancreatic Neuroendocrine Tumor, Pancreas Cancer | Phase 1 / Phase 2 | Withdrawn | University of Chicago | 2023-03-07 | 2024-10-26 | |
| Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer cytoreductive surgery - Cytoreductive Surgery | Not applicable | Not yet recruiting | Women's Hospital School Of Medicine Zhejiang University | 140 | 2022-12-01 | 2022-12-01 |
| Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer Cytoreductive surgery - Ovarian Cancer, Low Anterior Resection Syndrome | Recruiting | Seoul National University Hospital | 108 | 2022-06-22 | 2023-06-27 | |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer Carboplatin, Cisplatin, Cytoreductive Surgery - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Early Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2022-06-13 | 2026-08-17 |
| Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Atezolizumab, Bevacizumab, Biospecimen Collection - Peritoneal Malignant Mesothelioma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2022-03-22 | 2026-09-30 |
| Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) Cytoreductive surgery - Ovarian Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2022-01-07 | 2026-10-07 |
| Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer Paclitaxel, Carboplatin, debulking surgery - Ovarian Cancer | Phase 3 | Unknown | Fudan University | 200 | 2021-07-16 | 2022-05-12 |
| Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy debulking surgery - Ovarian Cancer Stage IV, Lymph Node Metastases | Completed | Seoul National University Hospital | 121 | 2021-06-01 | 2023-06-26 | |
| PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - Gastric Adenocarcinoma | Phase 2 | Recruiting | Banner Health | 30 | 2021-04-16 | 2026-05-01 |
| Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery Axitinib (VEGF-TKI), Cytoreductive Nephrectomy (CN), Metastasectomy (MET) - Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | University of California, San Francisco | 6 | 2021-02-09 | 2025-11-19 |
Showing 20 of 65. Sign in to see all of them.
Ovarian Neoplasms (26) · Peritoneal Neoplasms (17) · Fallopian Tube Neoplasms (11) · Colorectal Neoplasms (8) · Carcinoma, Ovarian Epithelial (6) · Stomach Neoplasms (6) · Adrenocortical Carcinoma (3) · Appendiceal Neoplasms (3) · Colonic Neoplasms (3) · Gastrointestinal Neoplasms (3) · Hyperthermia (3) · Neoplasms (3) · Adenoma, Islet Cell (2) · Brain Neoplasms (2) · Carcinoma (2)
National Cancer Institute (NCI) (5) · Hospices Civils de Lyon (3) · Memorial Sloan Kettering Cancer Center (3) · Andrew B Lassman, MD (2) · M.D. Anderson Cancer Center (2) · Masonic Cancer Center, University of Minnesota (2) · Seoul National University Hospital (2) · The University of Hong Kong (2) · University Hospital, Ghent (2) · Uppsala University (2) · A.O. Ospedale Papa Giovanni XXIII (1) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · Azienda Ospedaliera San Giovanni Battista (1) · Baki Topal (1) · Banner Health (1)
United States (25) · China (6) · Belgium (4) · France (4) · Germany (4) · Italy (4) · South Korea (3) · Spain (3) · Hong Kong (2) · Netherlands (2) · Sweden (2) · Canada (1) · Switzerland (1)
Aaron S Mansfield (1) · Aaron Shafer, MD (1) · Amy D. Tiersten, MD (1) · Andrea Hayes-Jordan, MD (1) · Andrew B. Lassman, MD (1) · Andrew G Renehan, PhD (1) · Andrew Lassman, MD (1) · Anna Solini, MD, PhD (1) · Armando Sardi, M.D. (1) · Baki Topal, MD, PhD (1) · Benedetto Bruno, MD (1) · Carol Aghajanian, MD (1) · David S Schrump, M.D. (1) · David Y Oh, MD, PhD (1)
PMID 11762804, PMID 14551293, PMID 14745444, PMID 16452199, PMID 16790085, PMID 19138791, PMID 19782876, PMID 19942597, PMID 20008305, PMID 21246515, PMID 21424369, PMID 24756812, PMID 26673788, PMID 26751236, PMID 26903580, PMID 27520560, PMID 27633880, PMID 27650694, PMID 28273222, PMID 29149865, PMID 29263704, PMID 30131226, PMID 30463745, PMID 31060544, PMID 31069579, PMID 31084544, PMID 31262599, PMID 32667582, PMID 37637060, PMID 37673112, PMID 37690994, PMID 37916797, PMID 37945326, PMID 38479803, PMID 41175449, PMID 41352872, PMID 42419336
2009 (1), 2015 (1), 2016 (1), 2025 (1), P30CA012197 (1), U10CA032102 (1), U10CA180821 (1)